Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized neoantigen vaccine 3
- Development stage
- Preclinical
- Lead developer
- NeoCura
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Personalized neoantigen vaccine 3 is a preclinical mRNA-based cancer vaccine developed by NeoCura. It is part of the NeoCura Ag™ platform, specifically the NeoCura™Ag-IND product line, which focuses on one-to-one customized therapies. The vaccine utilizes NeoCura's proprietary AI-driven ALPINE platform and deep learning MATHLA model to identify optimal patient-specific neoantigen fragments from tumor sequencing data. These fragments are then synthesized into coding mRNA preparations designed to elicit a robust and specific T-cell response against the patient's unique tumor profile. The candidate is currently being evaluated for the treatment of multiple tumor types.
- Other names
- NeoCura Ag-INDNeoCura Agpersonalized neoantigen vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Personalized neoantigen vaccine 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized neoantigen vaccine 3.